PI3K/mTOR双重抑制剂治疗肾癌的临床研究进展  

Clinical Research Progress of PI3K/mTOR Dual Inhibitors in Treatment of Renal Cancer

作　　者：王纯法 章俊 WANG Chunfa;ZHANG Jun(Pathological Teaching and Research Office,School of Clinical Medicine,Guizhou Medical University,Guiyang 550004,China;Department of Pathology,the Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China)

机构地区：[1]贵州医科大学临床医学院病理学教研室,贵阳550004 [2]贵州医科大学附属医院病理科,贵阳550004

出　　处：《医学综述》2023年第18期3615-3619,共5页Medical Recapitulate

摘　　要：磷脂酰肌醇-3-激酶/哺乳动物雷帕霉素靶蛋白(PI3K/mTOR)信号通路参与细胞的生长、凋亡、增殖等过程,在多种恶性实体瘤中异常表达。肾癌对放化疗不敏感,亟须寻找其他抗肿瘤治疗方案。PI3K/mTOR信号通路在肾癌中异常表达,PI3K/mTOR通路双重抑制剂具备使用剂量小、效价高等优势,但耐药现象限制了其在临床的应用。此外,单靶点药物在临床肾癌的治疗中也具有显著疗效。因此,深入研究PI3K/mTOR双重抑制剂治疗肾癌的机制,可以为疾病的治疗提供新思路。The signaling pathway of phosphatidylinositol-3-kinase/mammalian target of rapamycin(PI3K/mTOR)is involved in cell growth,apoptosis and proliferation,which is abnormally expressed in a variety of malignant solid tumors.Renal cancer is not sensitive to chemoradiotherapy,therefore it is urgent to find other anti-tumor treatment regimens.PI3K/mTOR signaling pathway is abnormally expressed in renal cancer,and dual inhibitors of PI3K/mTOR pathway have the advantages of low dosage and high potency,but their clinical application is limited due to drug resistance.In addition,single-target drugs also have significant efficacy in the treatment of clinical renal cancer.Therefore,in-depth study of mechanism of PI3K/mTOR dual inhibitors in the treatment of renal cancer can provide new ideas for the treatment of the disease.

关 键 词：肾癌 磷脂酰肌醇-3-激酶 哺乳动物雷帕霉素靶蛋白 双重抑制剂 

分 类 号：R979.1[医药卫生—药品]